본문으로 건너뛰기
← 뒤로

Tissue Injury and Biomaterial Treatment Modulate Tumor Growth and Response to Immunotherapy.

1/5 보강
bioRxiv : the preprint server for biology 2026
Retraction 확인
출처

Ruta A, Gray-Gaillard EF, Garcia JA, Davenport Huyer L, Mathkour Y, Cherry C, Patatanian M, Mejías JC, Maestas DR, Krishnan K, Abraham P, Wolf MT, Smith KN, Pardoll DM, Elisseeff JH

📝 환자 설명용 한 줄

Immunotherapies have transformed cancer care; however, tumor intrinsic and extrinsic factors contribute to high variability in therapeutic responses.

이 논문을 인용하기

BibTeX ↓ RIS ↓
APA Ruta A, Gray-Gaillard EF, et al. (2026). Tissue Injury and Biomaterial Treatment Modulate Tumor Growth and Response to Immunotherapy.. bioRxiv : the preprint server for biology. https://doi.org/10.64898/2026.02.02.703323
MLA Ruta A, et al.. "Tissue Injury and Biomaterial Treatment Modulate Tumor Growth and Response to Immunotherapy.." bioRxiv : the preprint server for biology, 2026.
PMID 41676614

Abstract

Immunotherapies have transformed cancer care; however, tumor intrinsic and extrinsic factors contribute to high variability in therapeutic responses. While tissue injuries can impact cancer recurrence and metastatic spread, little is known about their potential to effect immune checkpoint blockade (ICB) response. In this study, we reveal that distal traumatic muscle injury accelerated progression and impaired adjuvant ICB response of multiple murine tumors. This injury-induced accelerated tumor growth coincided with decreased intra-tumoral density and effector phenotype of tumor-reactive CD8 T cells and relied on communication through a shared draining lymph node. Enhancing injury repair using a biological scaffold abrogated the injury-induced accelerated tumor growth in an interleukin-4-dependent manner and improved ICB response. In a retrospective cohort analysis of breast cancer patients undergoing ICB treatment, biological scaffold implantation following mastectomy was associated with increased overall survival. This work suggests that injury-driven immune dysfunction may contribute to cancer progression and ICB resistance, but enhancing wound healing with pro-regenerative biomaterials may offer a viable strategy for mitigating adverse cancer outcomes, particularly in the setting of adjuvant and neoadjuvant ICB.